ERBB2 and gastroesophageal junction adenocarcinoma: The phase II trial is currently enrolling (NCT05190445) and will evaluate the efficacy of PRS-343 in combination with ramucirumab and paclitaxel in previously treated patients with treated HER2-overexpressing G/GEJ adenocarcinoma.